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Image-guided focused ultrasound ablation
of breast cancer: current status, challenges,
and future directions
Abstract Image-guided focussed ul-
trasound (FUS) ablation is a non-
invasive procedure that has been used
for treatment of benign or malignant
breast tumours. Image-guidance dur-
ing ablation is achieved either by
using real-time ultrasound (US) or
magnetic resonance imaging (MRI).
The past decade phase I studies have
proven MRI-guided and US-guided
FUS ablation of breast cancer to be
technically feasible and safe. We
provide an overview of studies asses-
sing the efficacy of FUS for breast
tumour ablation as measured by per-
centages of complete tumour necrosis.
Successful ablation ranged from 20%
to 100%, depending on FUS system
type, imaging technique, ablation
protocol, and patient selection. Spe-
cific issues related to FUS ablation of
breast cancer, such as increased treat-
ment time for larger tumours, size of
ablation margins, methods used for
margin assessment and residual tu-
mour detection after FUS ablation,
and impact of FUS ablation on senti-
nel node procedure are presented.
Finally, potential future applications
of FUS for breast cancer treatment
such as FUS-induced anti-tumour im-
mune response, FUS-mediated gene
transfer, and enhanced drug delivery
are discussed. Currently, breast-
conserving surgery remains the gold
standard for breast cancer treatment.
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Evolution of breast cancer treatment
Breast cancer is the most frequently occurring malignant
disease and leading cause of cancer-related death in women
in the Western world. The number of new cases and deaths
from breast cancer for women in the US in 2007 was
estimated to be 178,480 and 40,460, respectively [1].
Radical mastectomy, i.e., breast amputation with or without
excision of the pectoral muscle, has long been accepted as
an appropriate therapy for breast cancer.This treatment was
based on the theory of Dr. William Halsted that aggressive
local therapy for control of breast cancer, chest wall and
regional lymph nodes would have a substantial benefit on
survival [2]. In the 1970s, an increased understanding of
the natural history of breast cancer resulted in the use of
breast-conserving surgery, i.e., local excision as proposed
by Dr. Bernard Fisher, for treatment of breast cancer [3, 4].
After results of randomized studies demonstrated similar
survival rates for both treatment groups, breast-conserving
surgery combined with radiotherapy became standard
treatment for patients with localized breast cancer [3].
Parallel to this development, nationwide breast cancer
screening programmes were implemented in many Western
countries in the 1990s, resulting in an increased proportion
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Fax: +1-650-7367925of small carcinomas at time of diagnosis [5]. This further
facilitated the implementation of breast-conserving surgery
in clinical practice. However, the cosmetic outcome of
breast-conserving surgery is often suboptimal, this being
due to the fact that the resection of the tumour necessitate a
margin of 1 cm normal breast tissue and use of post-
operative radiation. Although breast-conserving surgery
carries a relatively low morbidity rate, a variety of
complications such as bleeding (2%-10%) and infections
(1%-20%) can occur [4].
Technological advances over the last decade have
fuelled interest in even less invasive treatment of patients
with localized breast cancer. Currently available minimally
invasive image-guided tumour ablation techniques include
radiofrequency ablation, cryoablation, laser ablation, mi-
crowave ablation, and focussed ultrasound (FUS) ablation
[6]. Different imaging modalities, including fluoroscopy,
ultrasound (US), and magnetic resonance imaging (MRI),
are used to guide instruments, to monitor the therapeutic
procedure and assess treatment response [7, 8]. Compared
with traditional surgical methods, minimally invasive
image-guided ablation therapies potentially offer several
advantages including reduced recovery time and hospital
stay, decreased complication risk (infections, bleeding),
and the ability to be performed under conscious sedation in
an outpatient setting, all factors leading to significant cost
reduction [7]. One of the most attractive image-guided
ablation therapies is FUS ablation. FUS ablation is a non-
invasive procedure, i.e., requires no probe insertion and
utilizes focussed ultrasound energy to coagulate tissue [9].
FUS ablation offers a promising method for noninvasive
treatment of benign or malignant breast tumours. The
breast is an organ with an excellent soft-tissue window that
is required for the ultrasound beam to reach the target
volume; furthermore, the breast can be easily immobilized.
This review outlines the current status and future directions
of image-guided FUS ablation for treatment of breast
cancer.
The basic concept of FUS ablation
Ultrasound beams are generated by a piezoelectric ultra-
sound transducer and propagate through tissue as a high-
frequency pressure wave. By focussing the ultrasound
beams to a focal spot at a certain distance from its source,
acoustic energy is converted to heat, and a sharp circum-
scribed lesion caused by thermal coagulation will be
produced [10]. The skin and tissue surrounding the tissue
lesion will be unaffected or show negligible temperature
rise [11]. The induced tissue lesion has a typical elliptical
shape and a volume of 50–300 mm (Fig. 1). For FUS
ablation, ultrasound beams with frequencies in the range of
0.5 to 4 MHz are used depending on the application type
and penetration depth that is to be attained, i.e., typical
penetration depth is 20 cm at 1.5 MHz. The temperature
reached within the focal point during a single sonication
should be between 60 and 95°C. The mechanism for cell
damage is primarily thermal [12]. Rapid increase in tissue
temperature above 56°C for 1s results in immediate protein
denaturation and coagulative necrosis. The extent of
cellular damage is determined both by the end temperature
achieved and length of time for which it is maintained [13].
At high ultrasound intensity levels, in addition to thermal
effect, mechanical stresses also occur, resulting in acoustic
cavitation and more extensive cell necrosis. In clinical
practice acoustic cavitation should be avoided because it
may result in unpredictable thermal lesions. Since a single
sonication creates a rather small tissue lesion and the need
for cooling between sonications necessary to protect tissue
heat accumulation and overheating, the time for treatment
of a breast tumour of several cm is rather long and ranges
from 45 min to 2.5 h. Several recent articles have reviewed
the basic physics of FUS for tissue ablation [13–15].
Choice of image guidance for FUS ablation
The potential application of FUS ablation for thermal
tumour destruction was demonstrated as early as 1942.
Lynn et al. reported focal lesions after FUS ablation in
mammalian brain tissue [16]. However, initial clinical
success of FUS ablation for treatment of neurological
conditions and solid tumours was hampered for decades by
the lack of reliable treatment monitoring and guidance
technology [17–20]. Developments in imaging technology
advanced the ability to use FUS effectively, and non-
invasive FUS ablation regained widespread scientific
momentum in the 1990s after integration of the ultrasound
treatment device with modern imaging system. This was
achieved in one of two ways, either by using real-time US
or MRI [9, 21]. Today, MRI is the most sensitive technique
for diagnosing breast cancer with a sensitivity approaching
100%. Furthermore, it is the most accurate imaging
Fig. 1 The typical elliptical shape of coagulated tissue after
focussed ultrasound ablation
1432modality for visualization and delineation of the breast
tumour margins [22–25]. Because MRI has an excellent
anatomical resolution and high sensitivity for tumour
detection, it offers accurate planning of the tissue to be
targeted. An additional advantage of MRI over other
imaging techniques is the possibility for MR-based tem-
perature mapping by exploiting the temperature depen-
dence of the water proton resonance frequency [26]. Proton
resonance frequency shift thermometry allows monitoring
temperature elevations during and after a focussed ultra-
sound sonication. Damage to adjacent structures can be
prevented by evaluation temperature elevations in the
surrounding tissue. As a consequence, by combining
focussed ultrasound as a noninvasive thermal therapy
with MRI for planning, guiding, monitoring, and control-
ling the focussed ultrasound beam, a real-time image-
controlled non-invasive breast tumour ablation system is
provided [13, 15]. The commercially available MRI-
guided FUS system consists of a FUS ablation device,
the ExAblate 2000™ (InSightec, Ltd., Haifa, Israel)
integrated in a 1.5-T or 3-T MRI magnet bore [General
Electric (GE) Medical Systems, Milwaukee, WI]. The MRI
magnet and the focussed ultrasound system are integrated
and controlled by a focussed ultrasound workstation and
console (Fig. 2). The system provides programmable
electronic control over the position and intensity of the
focal point across the volume of interest with high
flexibility, speed, and precision (Fig. 3).
Diagnostic ultrasound can also be used to guide the FUS
ablation procedure [21]. With US guidance, the field of the
diagnostic transducer is overlying and arranged parallel to
the therapeutic source and offers real-time visualization of
the targeted volume [27]. The shortcoming of ultrasound
for guiding ablation procedures in the breast is that in
general breast tumour size is underestimated with this
technique [24]. Accurate delineation of tumour marginsis a
significant limiting factor of ultrasound FUS guidance as
successful ablation of the tumour in its entire volume is
mandatory for successful outcome [28, 29]. Another
shortcoming of ultrasound guidance during breast tumour
ablation is the formation of gas bubbles in ablated tissue.
This results in reflection of the ultrasound waves and
acoustic posterior shadowing that influences the accuracy
for delineation of hypoechoic ablated tissue from hypo-
echoic breast tumour tissue [28]. Finally, the use of
ultrasound during breast tumour ablation is limited by its
inability to monitor temperature. Despite these short-
comings ultrasound has been used for noninvasive FUS
ablation of breast cancer, although all reports in this area
are from the same group [30–38]. Wu and colleagues also
developed the only commercially available US-guided
FUS ablation system (JC-HIFU system™, Haifu Technol-
ogy Co. Ltd., Chongqing, China).
MRI-guided FUS for breast tumour ablation
This first experience of MRI-guided FUS for treatment of
benign breast tumours was reported by Hynynen et al. in
2001 [39]. They described the use of MRI-guided FUS
ablation for treatment of 11 histologically proven breast
fibroadenomas. Treatment success was defined as complete
or partial lack of contrast material uptake on post-
procedural T1-weighted images, which was demonstrated
in 8/11 (73%) lesions. In three lesions the treatment was not
successful, which was attributed to low acoustic power and
patient movement. This report was followed in the same
year by the first case report of MRI-guided FUS for
Fig. 2 The ExAblate 2000™
FUS ablation device (InSightec,
Ltd., Haifa, Israel) with a built-
in 3-T MRI system [General
Electric (GE) Medical Systems[
in the Lucas MR Imaging Cen-
tre, Stanford, CA
1433treatment of a malignant breast tumour by Huber and
colleagues [40]. In this feasibility study a patient with a
core biopsy-proven invasive breast cancer was treated with
MRI-guided FUS 5 days prior to breast-conserving
surgery. Analysis of the breast tissue specimen revealed
areas of lethal and sublethal tumour damage, but no exact
percentage was provided. After these initial studies,
Gianfelice and colleagues were the first to report on the
accuracy of MRI-guided FUS for treatment of breast cancer
patients, according to a treat-and-resect protocol. In their
initial study 12 patients with invasive breast cancer were
treated with MRI-guided FUS prior to surgery [41].
Histopathologic analysis of resected tumour in nine
patients treated with the newest MRI-guided FUS system
showed that a mean of 88.3% cancer tissue was necrosed.
Residual tumour was in all cases observed at the periphery
of the tumour mass, indicating the need for larger (>5 mm)
safety margins around the MRI visible tumour. These
results were further supported by findings of the same
group in 17 patients with invasive breast cancer that were
treated with MRI-guided FUS prior to surgery [42].
Complete (100%) necrosis (Fig. 4) or less than 10%
residual tumour was observed in 13/17 (76%) lesions. This
study also provided evidence than contrast-enhanced MRI
was a reliable method to predict the presence of residual
tumour after MRI-guided FUS procedure. In agreement
with these findings, Zippel et al. reported the results of a
phase 1 trial on MRI-guided FUS ablation of breast cancer,
with use of the same ExAblate 2000 system [43]. They
treated ten patients 1 week prior to lumpectomy and
reported a range of results with complete necrosis in only
two patients (20%). Based on this result, it was concluded
that there are still several issues that need to be resolved
before MRI-guided FUS can become a standard therapeutic
technique for breast cancer treatment. They reported that
the precision of the focussed sound waves needs to be
perfected to destroy 100% of tumour tissue within the
lesion, as is achieved with breast-conserving surgery.
Secondly, as a surgeon attempts to remove a margin of
healthy tissue around the lesion to ensure negative margins,
they proposed that it may be necessary to increase the outer
limits of the MRI-guided FUS treatment zone to ensure
complete eradication of microscopic tumour foci.
In the study performed by Khiat et al. the effect of post-
treatment delay for evaluation of MR images on the
presence of residual cancer was assessed in 25 patients with
26 tumours [44]. Histopathological analyses following
MRI-gFUS showed no residual cancer in 8 lesions (31%),
less than 10% in 11 lesions (42%) and between 20–90% in
7 lesions (27%). They recommend an interval of
approximately 7 days to determine the effectiveness of
MRIgFUS, due to the fact that some benign processes, such
as oedema, fibrosis, necrosis, and inflammation, can mimic
for a malignant process in that period. More recently,
Furusawa et al. published improved results of MRI-guided
FUS for tumour ablation in a group of 30 breast cancer
patients [45]. All patients underwent surgery after FUS
ablation. On pathologic examination the mean percentage
of tumour necrosis was 97% of tumour volume. Fifteen
patients (50%) had 100% necrosis of the ablated tumour.
The first study on MRI-guided FUS ablation of breast
cancer as an adjunct to a preexisting tamoxifen citrate
Fig. 4 Excised breast tissue specimen after MRI-guided focussed
ultrasound ablation of a breast cancer, margins delineated with black
arrows
Fig. 3 Schematic diagram demonstrating breast cancer patient in
prone position and MRI-guided focussed ultrasound equipment
1434chemotherapeutic regimen for treatment of elderly, high-
risk surgical patients was reported by Gianfelice et al. in
2003 [46]. Since no surgical resection was performed after
MRI-guided FUS treatment, repeat large core-needle
biopsy and contrast-enhanced MRI were used to detect
foci of residual tumour. The total follow-up time was
6 months. Overall, 19/24 (79%) patients had negative
biopsy results after one or two MRI-guided FUS treatment
sessions. All patients completed at least one treatment
session. Recently, Furusawa et al. reported on the use of
MRI-guided FUS for local treatment of breast cancer in 21
patients: 17 patients were treated once and 4 patients twice
[47]. Mean follow-up was 14 months. During follow-up
patients underwent 3-monthly breast ultrasound and MRI
to detect residual tumour. Based on MRI findings, one case
(5%) of recurrence, i.e., mucinous carcinoma, was
detected. No evidence of recurrence was detected in the
other 20 patients (95%). However, results on the outcome
of MRI-guided FUS ablation of breast cancer in non-
surgical candidates need to be interpreted with caution,
since other adjuvant treatment regimens such as radiation
therapy and/or chemotherapy have likely influenced the
results. In all studies, MRI-guided FUS treatment was
performed under local anesthesia. Patients were given
analgesic and sedative agents intravenously to reduce pain,
unnecessary motion, and claustrophobia. All patients
tolerated the MRI-guided FUS procedure well, and only
one minor complication, a skin burn, was reported. An
overview of studies on MRI-guided FUS ablation of breast
tumours is provided in Table 1.
US-guided FUS for breast tumour ablation
Experience with ultrasound (US)-guided FUS ablation of
breast cancer is limited and has only been reported by Wu
et al. They reported three studies on the accuracy of US-
guided FUS ablation for breast cancer treatment [30, 33,
36]. In the first controlled clinical trial reported in 2003, a
total of 48 women were randomized in two treatment
groups: (1) the control group in which modified radical
mastectomy was performed (n=25) and (2) the US-guided
FUS ablation group, in which modified radical mastectomy
was performed within 1–2 weeks following ablation (n=
23) [36]. Of the patients that underwent US-guided FUS
ablation prior to surgery short-term follow-up (1–2 weeks),
pathologic and immunochemical stains were performed to
assess the therapeutic effect of ablation on breast tumour
tissue. Pathologic findings revealed that complete necrosis
was obtained with US-guided FUS ablation in all patients
(100%). The same result on therapeutic effect of US-
guided FUS ablation of breast cancer, i.e., 100% necrosis,
in the same patients was republished recently [30]. In this
most recent report Wu et al. described that a safety margin
of 1.5–2 cm around the US visible tumour was chosen to
ensure complete tumour ablation [30]. The patient cohort
of 23 US-guided FUS-treated patients served as a basis for
several other publications mainly focussing on the immu-
nohistochemical results as well [31, 32]. More recently, the
same group reported on US-guided FUS as adjunct to
chemotherapy, radiotherapy, and tamoxifen for treatment
of 22 patients with 23 malignant breast tumours (stage I to
IV) [33]. Post-procedural biopsy revealed coagulation
necrosis of the entire target tumour in all cases (100%).
After a median follow-up of 55 months, one patient died
(5%) and two patients (9%) developed local recurrence.
The 5-year disease-free survival was 95%. However, since
US-guided FUS was used in combination with radiother-
apy, chemotherapy, and tamoxifen, it is likely the
combination of treatment regimens that resulted in the
5-year survival of 95%. No skin burns or serious
complications (bleeding or infection) were observed. It is
remarkable that in all US-guided FUS ablation studies a
percentage of 100% tumour necrosis was achieved in all
patients. In general, this percentage clearly exceeds the
success percentage of MRI-guided FUS ablation, although
MRI is expected to be the most reliable imaging modality
for breast cancer detection and delineation. One potential
explanation could be that during the US-guided FUS
ablation a larger ablation margin was used (Table 2).
Obstacles for clinical implementation of breast FUS
ablation
Breast-conserving surgery is the gold standard
In the past decades, screening programmes and develop-
ment in breast imaging techniques have led to an increase
in the detection of early stage breast cancer [4]. Breast-
conserving surgery with radiotherapy has become the gold
standard treatment for localized breast cancer [3]. The
technique is easy to perform for qualified surgeons and
ensures tumour removal. Although breast-conserving sur-
gery is the standard treatment, positive margins are found
in between 10% and 53% of the patients [48, 49]. Factors
significantly associated with positive margins include large
tumour size, younger age, axillary lymph node-positive
status, and presence of extensive intraductal component
[49]. Furthermore, in breast-conserving surgery, although
categorized as a low-morbidity procedure, complications
such as bleeding (2%-10%), infection (1%-20%), seroma
formation (10%-80%) and chronic incisional pain (20%-
30%) occur [5].
To be equivalent to surgical removal, the effect of FUS
ablation should be to achieve total (100%) tumour necrosis.
Results of studies on FUS breast cancer ablation to date
have been variable, with histopathologic analysis demon-
strating complete tumour necrosis in 20% to 100% of
patients treated [30, 33, 36, 40–47]. Several factors may be
responsible for the variable outcome of FUS ablation.
Differences in patient selection, imaging techniques used,
1435Table 1 Overview of of studies on MRI-guided FUS ablation of breast tumours
Study Tumours
(n)
Breast tumour characteristics Outcome of the ablation procedure
1 Hynynen et al. (2001) [39] 11 - Fibroadenomas - No surgical resection
- Eight lesions (73%) demonstrated complete or partial
lack of contrast uptake (success)
- Three lesions (27%) showed no marked decrease of
contrast uptake (failure)
2 Huber et al. (2001) [40] 1 - Invasive ductal carcinoma (n=1) - Surgical resection
In the treated part of the tumour, cells were partly
necrotic and mostly sublethally damaged
No exact percentage is provided
3 Gianfelice et al. (2003) [42] 17 - Invasive ductal carcinoma (n=14) - Surgical resection
- Adenocarcinoma (n=2) - Complete necrosis in four lesions (24%)
- Infiltrating lobular carcinoma (n=1) - Less than 10% residual tumour in nine lesions (52%)
- All tumours <3.5 cm in size - Between 30–75% residual tumour in four lesions (24%)
4 Gianfelice et al. (2003) [46] 24 - Breast neoplasms, not specified - No surgical resection
- All tumours <2.5 cm in size - Complete necrosis after 1 or 2 treatments in 19 lesions
(79%)
- Residual tumour after two treatments (failure) in five
lesions (21%)
5 Gianfelice et al. (2003) [41] 12 - Invasive ductal carcinoma (n=11) - Surgical resection
- Adenocarcinoma (n=1) - Tumour necrosis 43.2% in three lesions (treated with
old FUS system)
- All tumours <3.5 cm in size - 88.3% tumour necrosis in nine lesions (treated with
new FUS system)
6 Zippel et al. (2005) [43] 10 - Breast neoplasms, not specified - Surgical resection
- All tumours <3 cm in size - Complete necrosis in two lesions (20%)
- Microscopic foci of residual tumour in two lesions
(20%)
- 10% residual tumour in three lesions (30%)
- Between 10–30% residual tumour in three lesions
(30%)
7 Khiat et al. (2006) [44] 26 - Invasive ductal carcinoma (n=25) - Surgical resection
- Infiltrating lobular carcinoma (n=1) - Complete necrosis in seven lesions (27%)
- All tumours <3.5 cm in size - Less than 10% residual tumour in 11 lesions (42%)
- Between 20–90% residual tumour in seven lesions
(27%)
- Outcome of one lesion is missing (4%)
8 Furusawa et al. (2006) [45] 30 - Invasive ductal carcinoma (n=26) - Surgical resection
- Ductal carcinoma in situ (n=3) - Mean necrosis of targeted breast tumours was 96.9%
- Invasive mucinous carcinoma (n=1) - Complete necrosis in 15 lesions (50%)
- All tumours <3 cm in size - Between 95%-100% necrosis in 12 lesions (36%)
- Less than 95% necrosis in three lesions (4%)
9 Furusawa et al. (2007) [47] 21 - Breast neoplasms, not specified - No surgical resection
- All tumours <5 cm in size - Mean follow-up 14 months (range 3–26 months)
- Complete necrosis in 20 lesions (95%)
- One recurrence (5%)
1436and tumour ablation protocols are three factors, but one of
the most critical factors may be the size of ablated margins,
i.e., healthy breast tissue surrounding the tumour that is to
be ablated as part of the procedure.
Size of the ablation margins
Several studies have examined the importance of tumour-
free surgical margins after breast-conserving therapy [50].
Ideally the tumour along with a margin of at least 10 mm of
normal-appearing tissue is resected to attempt to remove
any microscopic cancerous tissue in the region [49]. The
minimum cosmetically acceptable tumour-free margin in
relation to the risk of local or distant recurrence has been
debated in many studies [48, 50–52]. For image-guided
FUS ablation successful treatment of the entire tumour
relies on accurate tumour volume delineation with the
imaging technique (US or MRI) used for targeting and
monitoring the ablation procedure. In this respect MRI is
most accurate imaging technique currently available [22].
MRI may also underestimate tumour size, especially when
an extensive ductal carcinoma in situ (DCIS) component is
present [25]. To address the problem of tumour size
underestimation and ensure total tumour ablation, different
groups have proposed ablation of a margin of “healthy”
breast tissue surrounding the breast tumour during FUS
treatment. Gianfelice et al. reported in their study that the
residual tumour cells were mainly found at the periphery of
the treatment field and proposed that this was caused by
lack of ablating an adequate amount of surrounding healthy
breast tissue around the tumour [41]. Wu et al. treated 1.5–
2.0 cm of normal tissue surrounding the tumour and found
no residual cancer in all patients [30]. Based on breast-
conserving therapy studies, the tumour and a margin of at
least 10 mm healthy breast tissue should be ablated to
increase the probability of complete tumour necrosis [41].
Methods for margin assessment and residual tumour
detection after FUS ablation
If FUS is to be implemented in clinical breast cancer
treatment as an alternative to conventional surgery in the
future, a reliable method for tumour margin assessment and
detection of residual tumour after FUS ablation must be
available. Since FUS treatment would lack a surgically
excised pathological specimen, the tumour margin status
could not be assessed by histopathological analysis. To
date, most protocols have been treat-and-resect protocols,
i.e., FUS ablation followed by surgery, which allows
histopathological tissue examination to evaluate the ther-
apeutic effect of FUS. In the few FUS ablation studies
where treated tumour tissue was left in situ after ablation,
different strategies have been used to assess outcome.
Furusawa et al. used clinical follow-up by MRI and US
every 3 months [47]. If one of the modalities showed
suspicious findings suggestive for residual tumour, large
core-needle biopsy (LCNB) of the lesion was performed,
and if residual tumour or tumour recurrence was found, the
Table 2 Overview of of studies on ultrasound-guided FUS ablation of breast tumours
Study Tumours
(n)
Breast tumour characteristics Outcome of the ablation procedure
1 Wu et al. (2003)* [36] 23 - Invasive breast cancer, not specified
(n=21)
- Surgical resection
- Non-invasive breast cancer, not
specified (n=2)
- Complete necrosis in 23 lesions (100%)
- All tumours <6 cm in size - Only TTC staining used
2 Wu et al. (2005) [33] 23 - Invasive breast cancer, not specified
(n=21)
- No surgical resection
- Non-invasive breast cancer, not
specified (n=1)
- Follow-up range 3–60 months
- Missing (n=1) - Complete necrosis initially (2 weeks) in 23 lesions
(100%)
- All tumours <5 cm in size - Local recurrence (after 18 and 22 months, respectively)
in two lesions (9%)
3 Wu et al. (2007)* [30] 23 - Invasive breast cancer, not specified
(n=21)
- Surgical resection
- Non-invasive breast cancer, not
specified (n=2)
- Complete necrosis in 23 lesions (100%)
- All tumours <6 cm in size - Only TTC staining used
*Both studies report on the same patient population treated with US-guided FUS
1437affected area was treated again with FUS ablation.
Gianfelice et al. used MRI follow-up at 10 days, 1, 3 and
6 months post-treatment to detect residual disease after
FUS ablation in high-risk surgical patients [46]. Additional
to imaging, after 6 months, multiple LCNBs were
performed through different areas of the ablation zone. In
case of residual tumour, a second FUS procedure was
performed and followed by another targeted LCNB
1 month later. The technique of LCNB for residual tumour
detection along the ablation zone margins was also used by
Wu et al. They performed LCNB at 2 weeks, 3 months,
6 months and 12 months post-treatment [33]. In case of
residual tumour patients were subsequently treated with
modified radical mastectomy. Although no definitive
guidelines are available today, the combination of con-
trast-enhanced breast MRI and multiple LCNBs for
residual tumour detection appears to be the most promising
strategy for candidates after FUS treatment where the
treated tumour is left in situ.
Selection of appropriate patients for FUS ablation
Another important issue for successful FUS ablation is
appropriate patient selection. Some breast cancer patients
cannot be scheduled for FUS ablation for technical reasons.
For FUS treatment a distance of at least 1 cm between the
tumour and the skin (to avoid skin burn) and tumour and
chest wall (to prevent heat accumulation in the underlying
ribs and lung) is required [35]. For MRI-guided FUS
ablation, it is also required that, apart from the standard
MRI contra-indication, patients must lie still in the closed
bore MRI magnet for a long period of time, which can be
physically and psychologically difficult, especially in
anxious or claustrophobic patients [27]. When FUS
ablation is performed for curative treatment of breast
cancer, preferentially, patients with large tumours (>5 cm)
should not be selected for FUS ablation as increased
tumour size significantly increases the treatment time and
the probability of complete tumour necrosis decreases
substantially [42]. Although there are no guidelines
concerning the inclusion of patients based on the tumour
size, results from the breast cancer radiofrequency ablation
studies showed consistent 100% ablation in patients treated
with breast cancers ≤2 cm in size [29, 53]. Another issue
that needs to be investigated is the effect of different
biological tumour characteristics, i.e., ER/PR and her2neu
status of the breast cancer cells, on the outcome of the FUS
ablation. So far, no data are available addressing this issue.
Additionally, patients diagnosed with extensive DCIS
should be excluded from FUS ablation. The diagnostic
value of MRI for detecting and predicting tumour size of
DCIS is still controversial. Although a recent study showed
a high sensitivity of MRI (up to 98%) for the detection of
DCIS [54], other study results revealed that MRI tends to
under- or overestimate the extent of DCIS tumours in 17–
77% and 11–19% of the patients [55–57], hence the use of
image-guided FUS ablation may result in overtreatment or
more importantly undertreatment of the DCIS component.
When FUS ablation is applied for local tumour control in
non-surgical candidates with locally advanced breast
cancer or metastatic breast disease, the two issues of
tumour size and extensive intradutcal tumour component
are less important [46]. In these patients it is important that
FUS ablation is a well-tolerated, low-morbidity, and
repeatable method for tumour ablation that allows local
disease control.
Impact of FUS ablation on sentinel node procedure
For breast cancer patients, information about the presence
of metastases in regional axillary lymph nodes is an
important prognostic factor. Sentinel lymph node biopsy
(SLNB) is a validated minimally invasive diagnostic
procedure used to determine the status of regional lymph
nodes for staging purposes [58–61]. Theoretically, FUS
might affect the accuracy of the sentinel lymph node
procedure by obstructing or alternating the anatomy of
breast lymphatics or lymph drainage. Zippel et al.
performed sentinel node biopsy in two of their patients
treated with FUS [43]. Although a small group, there were
no technical problems in finding the sentinel node by the
use of contrast agent and radio-isotope-guided surgery.
Vargas, et al. conducted a study to determine the success
rate of SLNB in patients enrolled in a clinical trial of pre-
operative focussed microwave phased-array tumour abla-
tion [60]. Sentinel nodes were found with an overall
success rate of 91%, which is comparable with other
reports on success rate of SLNB in the literature [58, 59,
61]. Although these results imply that there might be no
impairment in the ability to perform sentinel node biopsy
after ablation with focussed ultrasound, further investiga-
tion is necessary.
Potential future applications of FUS ablation
Although most of the FUS research focusses on thermal
ablation for localized thermal treatment of breast cancer, it
has been reported that thermal and mechanical damage of a
primary tumour by FUS may trigger systemic biological
responses in vivo as well. FUS tumour ablation creates a
large amount of tumour antigens in the form of necrotic
cells and damaged tumour cells, which may trigger
dendritic cell activation. This mechanism may play a
critical role in FUS-induced anti-tumour immune response.
This hypothesis was recently tested in mice implanted with
adenocarcinomas and treated with thermal and mechanical
FUS ablation in order to assess FUS-induced effects on the
mice’s immunological response, as expressed by in vivo
dendritic cell activity [62]. The results confirmed that
1438mechanical FUS ablation resulted in a systemic anti-
tumour immune response and that the response is related to
dendritic cell activation. The advantage of a systemic anti-
tumour immune response is attack of residual tumour cells
at the primary treatment site, but also potentially suppres-
sion of distant metastases.
Another potential therapeutic application is FUS-
mediated gene transfer [63]. One of the key challenges in
cancer gene therapy is spatial and temporal control of
transgene expression in the tumour cells. In animal models
FUS-induced hyperthermia has been successfully used to
induce precise focal transgene expression in targeted
tumour tissue [64]. This has been achieved by using a
heat-sensitive promoter, usually the heat shock protein
(hsp)70B promoter and a reporter gene, such as green
fluoresecent protein (GFP) or firefly luciferase (Fluc) for in
vivo monitoring of accuracy and effectiveness of FUS-
mediated transgene expression [65]. Future research will
focus on FUS hyperthermia-induced activation of a
therapeutic (trans) gene, such as tumour necrosis factor α
or interleukin 12.
FUS hyperthermiahasalsobeenstudiedinanimalmodels
for targeted chemotherapy to solid tumours. Since conven-
tional chemotherapeutic regimens cause systemic toxicity,
developing strategies for improved targeted chemotherapeu-
tic delivery is of great clinical interest. One method used for
targetedchemotherapyistheuseofheat-sensitiveliposomes.
In this method the chemotherapeutic drug is encapsulated in
the liposome, which results in prolonged intra-vascular
circulation time. Because malignant tumours are associated
with neo-angiogenesis resulting in leaky vessels, liposomes
willpreferentiallyaccumulateintheinterstitiumsurrounding
the tumour [66]. FUS-induced hyperthermia will enhance
both extravasation and drug release when these heat-
sensitive liposomes are used [67, 68]. Contrary to these
studies that have shown enhanced drug delivery using FUS,
results of a recent study assessing FUS for enhanced uptake
of liposome-encapsulated doxorubicin in a mouse breast
cancer model were disappointing [69]. Further studies are
required to investigate the exact mechanisms by which FUS
hypethermia may induce targeted drug release and define
which therapeutic agents should be used.
Conclusion
FUS ablation has the potential to become an important
modality for non-invasive image-guided treatment of
localized breast cancer. Multiple phase I studies have
proven MRI-guided and US-guided FUS ablation of breast
cancer to be technically feasible and safe. The reported
efficacy of FUS ablation as measured by percentages of
complete tumour necrosis ranged from 20% to 100%. The
difference in outcome between FUS ablation studies can be
explained by differences in patient selection, imaging
techniques, and tumour ablation protocols used. Although
the results of US-guided and MRI-guided FUS ablation are
promising, the data are too scant to justify a randomized
controlled trial that compares FUS ablation with breast-
conserving surgery for treatment of localized breast cancer.
To date, MRI-guided treatment protocols of breast tumours
offer the most accurate imaging technique for breast
tumour targeting, breast tumour delineation, treatment
monitoring (including temperature mapping), anddetection
of residual disease after treatment. The next step towards
clinical implementation of FUS for breast tumour ablation
would be a large prospective treat-and-resect study that
assesses the therapeutic efficacy of MRI-guided FUS
ablation in patients with small (<2 cm) solitary breast
cancers and provides data that can be used for technique
standardization and guideline formulation. In addition,
FUS for anti-tumour immune response induction, con-
trolled transgene expression, and targeted drugs delivery in
breast cancer patients should be explored. Currently,
breast-conserving surgery remains the gold standard for
breast cancer treatment.
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